De novo design of miniprotein-based natural killer cell engagers
ฝัง
- เผยแพร่เมื่อ 9 ก.พ. 2025
- Presented on December 11th 2024 by Mireia Solà Colom
Abstract:
Immune cell engagers are a promising modality for cancer therapy, but many limitations must still be overcome before this approach will reach its full potential. De novo-designed miniproteins allow engineering high-valency immune cell engagers equipped with any imaginable functionality while allowing sophisticated control over on-cell binding, immune cell activation and immune synapse formation.